HexemBio Raises $10.4M Seed to Advance Blood Stem Cell Rejuvenation Therapies
Most seed rounds feel like a press release dressed up as momentum. This one feels like a lab result you cannot ignore. HexemBio, the NYC-based biotechnology company developing blood stem cell rejuvenation therapies, just raised $10.4M in Seed funding, led by Draper Associates with participation from SOSV, Seraphim Space, and other investors. That is not just money hitting an account. That is conviction landing on a very specific idea: maybe the future of medicine is not about bullying biology into submission, but reminding it what it knew before age, stress, and time started acting like cheap furniture on a bad floor.
HexemBio is building what it calls the first blood stem cell rejuvenation therapy through its Synthetic Human Yolk Sac platform. Read that again slowly. Most people hear “yolk sac” and think breakfast. HexemBio hears developmental biology and sees an opening. The company is recreating the early environment where hematopoietic stem cells first emerge, then exposing a patient’s own aged stem cells to that niche outside the body before returning them through a standard IV infusion. No genetic modification. No chemical reprogramming. Just a cleaner swing at restoring function where the trouble starts.
That kind of premise does not get serious people to lean in unless the science has teeth. It does. The founding team includes Gabriel Levesque Tremblay, PhD, CEO and Co-Founder, Samira Kiani, MD, CTO and Co-Founder, Mo Ebrahimkhani, MD, CSO and Co-Founder, Samet Yildirim, MBA, CBO and Co-Founder, and Joshua Hislop, PhD, Head of AI and Co-Founder. This is a crew built across synthetic biology, clinical medicine, AI, drug development, and commercialization. Not a costume party. A company.
The capital will help HexemBio finalize IND-enabling studies and GMP manufacturing, with first-in-human trials targeted for 2027. That matters because biotech is one of the few arenas where storytelling can open the door, but only execution gets a chair. Regulatory groundwork, manufacturing discipline, and a path into the clinic are where ambition stops posing and starts working.
A business lesson sits in plain sight. HexemBio did not raise around a vague promise to “change everything.” HexemBio raised on a sharp thesis, credible science, and a use of funds that tells investors exactly what comes next. Draper Associates, SOSV, Seraphim Space, and the rest did not back noise. They backed sequencing, focus, and a team that understands the distance between a beautiful idea and a therapy that can actually meet a patient.
Congratulations to Gabriel Levesque Tremblay, Samira Kiani, Mo Ebrahimkhani, Samet Yildirim, Joshua Hislop, and the entire HexemBio team. In a market flooded with pitch decks dressed like prophecy, HexemBio is doing something much rarer. It is making blood work a little harder, and making the rest of the industry pay attention.
